prof-georgina-long

Professor Georgina Long AO

BSc PhD MBBS FRACP FAHMS AAHMS FAA

Medical Director

Professor Georgina Long AO, BSc (Hons1, UM) PhD MBBS (Hons) FRACP FAHMS AAHMS FAA, is Medical Director of Melanoma Institute Australia (MIA), and Chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, The University of Sydney. She leads an extensive clinical trials team and laboratory at MIA, with a focus on targeted therapies and immuno-oncology in melanoma. She is the chief investigator on NHMRC funded research into the molecular biology of melanoma, with a particular interest in clinical and tissue biomarker correlates of systemic therapy sensitivity and resistance.

In recognition of her ground-breaking research and work, Professor Long was named 2024 Australian of the Year and was awarded Fellowship with the Australian Academy of Science (2024), recognized with the Australian Academy of Health and Medical Sciences Outstanding Female Research Medal (2021) and was appointed as an Officer of the Order of Australia (2020). Professor Long has also received numerous awards, including Fulbright U.S. Mission Australia Award for Leadership Excellence (2024), ESMO Women for Oncology Award (2023), Sydney Local Health District/Sydney Research 2022 Research Excellence Award (2022) the prestigious Ramaciotti Medal for Biomedical Research (2021), Vice Chancellor’s Award for Excellence Award for Outstanding Research (2021), University of Sydney (2021), Research Australia GSK Research Excellence Award (2018) and the Sir Zelman Cowen Universities Fund Prize for Discovery in Medical Research (2016). She has a number of CINSW Premiers Awards, including; the Outstanding Cancer Researcher (2018), the Excellence in Translational Cancer Research Award (2017), the Wildfire Award for the most highly-cited, original, peer-reviewed article published (2011, 2014, 2016, 2017, 2018, 2019 & 2020), and in 2013 she was named the Outstanding Cancer Research Fellow.  She is also Clarivate highly-cited Researcher for 2017-2024.  Her H index is 149 and in March 2025 she was ranked the world’s equal 1st melanoma expert in all fields and discipline (https://expertscape.com/ex/melanoma)

Professor Long is the author of over 570 peer-reviewed publications in clinical and translational research in melanoma, including the New England Journal of Medicine, Lancet, Lancet Oncology, Science, Nature, Journal of Clinical Oncology and Cancer Discovery.  Professor Long has presented her work at international conferences and meetings on more than 300 occasions. She is Past President for the prestigious international Society for Melanoma Research (President 2018-2020), is a member and Chair of the ASCO (2015-2017) and ESMO (2017-2020 & 2026 – 2029) Scientific Committee for Melanoma/Skin cancer, is medical oncology lead for the Australian Melanoma Management Guidelines Committee, and is member of both the ASCO Plenary Series and ASCO AGM Education committees (2021-2024), Scientific Co-Chair for ESMO Asia (2024) and EADO (2026). She is on the editorial boards of several high-impact journals, and is a member of the Melanoma Expert Panel for AJCC Cancer Staging System 8th edition.

 Professor Long was awarded the University Medal in Organic Chemistry. She subsequently completed her PhD in Chemistry in the field of anti-cancer agents and their binding to DNA. She then moved to the USA to take up a Fulbright Postdoctoral Fellowship at Scripps Research Institute, exploring nanotechnology in cancer treatment, before returning to Australia to complete her MBBS (Hons). Professor Long became a Fellow of the Australasian College of Physicians in January 2008, specialising in medical oncology.

Please follow Georgina on social:
Twitter: @ProfGLongMIA
Instagram: @profglong

Contact details 

For all media enquiries, please email media@melanoma.org.au

To make a medical appointment to see Prof Georgina Long AO, or for any clinical concerns, please email smo_reception@melanoma.org.au

To contact Professor Georgina Long AO on all other matters, please email her Executive Assistant, Karen Bush at ealong@melanoma.org.au

Prof Long Recent News

Prof Long Recent Publications

Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.

2025-03-27T13:56:32+11:00February 7th, 2025|Tags: , , , , |

Kennedy OJ, Glassee N, Kicinski M, Bührer E, Valpione S, Gandini S, Suciu S, Blank CU, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Boers-Sonderen M, Di Giacomo AM, van den Eertwegh AJM, Grob J-J, Gutzmer R, Jamal R, van Akkooi ACJ, Robert C, Eggermont AMM, Lorigan P, Mandala M. EJC Skin Cancer, (Feb 07 2025): 100284, doi:https://doi.org/10.1016/j.ejcskn.2025.100284.

|

Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance.

2025-04-07T12:33:21+10:00February 6th, 2025|

Newell F, Pires da Silva I, Johansson PA, Menzies AM, Wilmott JS, Addala V, Carlino MS, Rizos H, Nones K, Edwards JJ, Lakis V, Kazakoff SH, Mukhopadhyay P, Ferguson PM, Leonard C, Koufariotis LT, Wood S, Blank CU, Thompson JF, Spillane AJ, Saw RPM, Shannon KF, Pearson JV, Mann GJ, Hayward NK, Scolyer RA, Waddell N, Long GV. Cancer Cell, (Feb 06 2025), doi:https://doi.org/10.1016/j.ccell.2025.01.011. TOP 10%

|

Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma.

2025-03-27T15:21:31+11:00February 3rd, 2025|

Munoz-Couselo E, Soria Rivas A, Sandhu S, Long GV, Sanmamed MF, Spreafico A, Buchbinder E, Sznol M, Prenen H, Fedenko A, Milhem M, Arance Fernandez AM, Grob JJ, Demidov L, Robert C, Habigt C, Evers S, Sleiman N, Dejardin D, Ardeshir C, Martin N, Boetsch C, Charo J, Teichgraeber V, Kraxner A, Keshelava N, Bechter O. Cancer Res Commun, (Feb 3 2025), doi:10.1158/2767-9764.Crc-24-0601.

|

Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial.

2025-03-31T15:51:39+11:00February 1st, 2025|Tags: , , , , , , |

Yoon CH, Ross MI, Gastman BR, Luke JJ, Ascierto PA, Long GV, Rutkowski P, Khattak M, Del Vecchio M, de la Cruz Merino L, Mackiewicz J, Chiarion-Sileni V, Schadendorf D, Carlino MS, Zhao Y, Fukunaga-Kalabis M, Krepler C, Eggermont Alexander MM, Gershenwald JE, Sondak VK. Annals of Surgical Oncology, (Feb 01 2025), doi:10.1245/s10434-024-16642-6.

|

Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey.

2025-03-27T13:42:04+11:00January 1st, 2025|

Hauschild A, Garbe C, Ascierto PA, Demidov L, Dreno B, Dummer R, Eggermont A, Forsea A-M, Gebhardt C, Gershenwald JE, Hamid O, Hoeller C, Kandolf L, Kaufmann R, Kirkwood JM, Lebbé C, Long GV, Malvehy J, Martin-Algarra S, McArthur G, Neyns B, Richtig E, Robert C, Schadendorf D, Scolyer R, Sondak VK, Wainstein A, Weichenthal M, Nuti P, Aarts MJB, Arance A, Asher N, Berciano-Guerrero M-A, Berking C, Carlino MS, Dabelić N, Davar D, Espinosa E, Forschner A, Gaide O, Gaudy-Marqueste C, Gavrilova I, Grabbe S, Gutzmer R, Hafner C, Hassel JC, Jacobs C, Jang S, Kähler KC, Kehrer H, Koelblinger P, Leiter U, Lipson EJ, Livingstone E, Luke JJ, Mandalà M, Mangana J, Marić Brozić J, Marquez-Rodas I, Maul LV, Mazilu L, Mehmi I, Meier F, Mesti T, Mitchell TC, Mohr P, Moyers J, Muñoz Couselo E, Najjar YG, Nakamura Y, Ocvirk J, Orlova K, Popescu BC, Popovic A, Posch C, Queirolo P, Ramelyte E, Roberts-Thomson R, Rorive A, Ruhlmann CH, Rutten A, Salama AKS, Samoylenko I, Schilling B, Shalamanova-Deleva G, Siano M, Smithy JW, Stelzhammer P, Suijkerbuijk K, Terheyden P, Teterycz P, Tietze JK, Urbonas V, Utyashev I, van der Veldt AAM, Venter M, Zarour HM, Zimmer L, Zinovev G. The Lancet Oncology, 26, no. 1, (Jan 2025): 12-14, doi:10.1016/S1470-2045(24)00627-2. TOP 10%

|
TAKE STEPS TO HELP SAVE LIVES
Go to Top